Associated tags: Chronic obstructive pulmonary disease, Inflammation, Therapy, Alzheimer's disease, VTV, COPD, Pharmaceutical industry, Patient, Insulin, Receptor (biochemistry), FDA, RAGE, T1D, Cancer
Locations: HIGH POINT, NC, US, MIDDLE EAST
FDA,
T2D,
Insulin,
G42,
Expense,
Administration,
Disease,
Incidence,
Research and development,
Patient,
VTV,
Clinical trial,
Therapy,
G&A,
Pharmaceutical industry “The first quarter of 2024 saw us reach several important milestones, which we believe position vTv well for continued execution of our corporate and clinical development strategy,” said Paul Sekhri, Chief Executive Officer of vTv.
Key Points:
- “The first quarter of 2024 saw us reach several important milestones, which we believe position vTv well for continued execution of our corporate and clinical development strategy,” said Paul Sekhri, Chief Executive Officer of vTv.
- Site activation activities for this trial are well underway and we continue to expect enrollment of the first patient during the second quarter.
- Net Loss: Net loss attributable to vTv shareholders for the three months ended March 31, 2024, was $4.9 million or $1.17 per basic share.
- Net loss attributable to vTv shareholders for the comparable period a year ago was $4.5 million or $2.16 per basic share.
Retrieved on:
Wednesday, March 13, 2024
CGM,
Administration,
G42,
IROS,
Type 2 diabetes,
Incidence,
Insulin,
Patient,
Level 2,
G&A,
Doctor of Philosophy,
MD,
VTV,
Clinical research associate,
Research and development,
Therapy,
JDRF,
PIPE,
Safety,
Saṃsāra,
FDA,
Pharmaceutical industry HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
Key Points:
- In connection with the PIPE, vTv has reduced the size of its Board of Directors from nine to seven members.
- HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
- Net Loss: Net loss attributable to vTv shareholders for the year ended December 31, 2023, was $20.3 million or $9.71 per basic share.
- Net loss attributable to vTv shareholders for the comparable period a year ago was $19.2 million or $9.98 per basic share.
Incidence,
CGM,
Doctor of Philosophy,
Level 2,
MD,
FDA,
Quality of life,
IROS,
Safety,
Diabetes,
Therapy,
Type 2 diabetes,
Patient,
Insulin,
T1D,
Pharmaceutical industry This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024.
Key Points:
- This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024.
- The Phase 3 study will assess two doses of orally administered cadisegliatin versus placebo in patients currently being treated with multiple daily insulin injections and continuous subcutaneous insulin infusion, who use a continuous glucose monitor (CGM).
- The primary efficacy endpoint of the study will compare the incidence of Level 2 or Level 3 hypoglycemic events between cadisegliatin-treated subjects and those in the placebo group.
- Cadisegliatin is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.
HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that Company management will be presenting at the TD Cowen 44th Annual Healthcare Conference, being held March 4-6, 2024, in Boston, MA.
Key Points:
- HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that Company management will be presenting at the TD Cowen 44th Annual Healthcare Conference, being held March 4-6, 2024, in Boston, MA.
- The presentation is scheduled for Tuesday, March 5, 2024, at 9:50 AM ET.
- Investors interested in scheduling a one-on-one meeting with vTv’s management should contact their TD Cowen representative.
Retrieved on:
Wednesday, February 28, 2024
JDRF,
Doctor of Philosophy,
Saṃsāra,
MD,
Sale,
Exercise,
VTV,
Therapy,
Insulin,
PIPE,
Security (finance),
Research,
VWAP,
Pharmaceutical industry Additional information regarding the composition of the Board is available in a Current Report on Form 8-K filed with the SEC.
Key Points:
- Additional information regarding the composition of the Board is available in a Current Report on Form 8-K filed with the SEC.
- vTv expects to use the proceeds from the PIPE to fund the first Phase 3 study of its lead product candidate, cadisegliatin, which is expected to initiate in mid-2024.
- JDRF is the world’s largest nonprofit funder of T1D research focused on accelerating cures, preventing, and treating T1D.
- There are more than 18 million people living with T1D worldwide with fewer than 30% meeting their A1c targets, demonstrating the clear need for additional therapies.
Retrieved on:
Thursday, February 22, 2024
WESTON, Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.
Key Points:
- WESTON, Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.
- During the conference, Dr. Marcus will conduct one-on-one meetings with registered investors, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
- Cantex is developing azeliragon, an oral inhibitor of the receptor for advanced glycation end products (known as RAGE).
- Cantex has ongoing Phase 2 clinical trials in top US and EU medical centers in glioblastoma, brain metastasis, metastatic pancreatic cancer, and breast cancer, and a Phase 3 randomized, placebo-controlled clinical trial in hospitalized patients with pneumonia.
Retrieved on:
Thursday, November 9, 2023
Research and development,
Therapy,
Insulin,
Expense,
Administration,
VTV,
G&A,
General Administration of Customs,
R,
Receptor (biochemistry),
Pharmaceutical industry HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.
Key Points:
- HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.
- Cash Position: The Company’s cash position as of September 30, 2023 was $8.2 million compared to $12.1 million as of December 31, 2022.
- Net Loss: Net loss attributable to vTv shareholders for the three months ended September 30, 2023 was $6.7 million or $0.08 per basic share.
- Net loss attributable to vTv shareholders for the comparable period a year ago was $4.3 million or $0.05 per basic share.
Retrieved on:
Wednesday, November 8, 2023
HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that its Chief Financial Officer, Steven Tuch, its Chief Scientific Officer, Carmen Valcarce, and its Chief Medical Officer, Thomas Strack, will be presenting at the Stifel 2023 Healthcare Conference on November 15, 2023, at 9:45 AM EST.
Key Points:
- HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that its Chief Financial Officer, Steven Tuch, its Chief Scientific Officer, Carmen Valcarce, and its Chief Medical Officer, Thomas Strack, will be presenting at the Stifel 2023 Healthcare Conference on November 15, 2023, at 9:45 AM EST.
- Investors interested in scheduling a one-on-one meeting with vTv’s management should contact their Stifel representative.
Retrieved on:
Thursday, November 2, 2023
Knowledge,
Medical Affairs Bureau,
FDA,
Therapy,
Clinical research,
National Association Medical Staff Services,
Breakthrough,
Eli Lilly,
Daiichi Sankyo,
Research,
Drug development,
Eli Lilly and Company,
VTV,
T1D,
Patient,
Consultant,
University of Mainz,
Insulin,
Pharmaceutical industry,
Oncology,
Pfizer as Chief Medical Officer, effective immediately.
Key Points:
- as Chief Medical Officer, effective immediately.
- “I am pleased to welcome Dr. Strack to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics.
- Most recently, he served as Chief Medical Officer of Faeth Therapeutics Inc., a clinical stage developer of metabolic oncology therapies.
- He also served as Consultant in Medical Affairs at Omeros Corporation, a clinical stage biopharmaceutical company focused on small-molecule and protein therapeutics for immunologic disorders.
Retrieved on:
Wednesday, November 1, 2023
“The proceeds from the sale of our Reneo stock will provide vTv with important financial support as we continue our preparations for the launch of the cadisegliatin Phase 3 program in T1D.
Key Points:
- “The proceeds from the sale of our Reneo stock will provide vTv with important financial support as we continue our preparations for the launch of the cadisegliatin Phase 3 program in T1D.
- We remain in active discussions related to the financing, partnering and/or licensing of cadisegliatin,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics.
- “We are excited about the therapeutic potential of mavodelpar and look forward to Reneo’s upcoming data readout.
- Reneo’s lead program, mavodelpar, is a PPARδ agonist currently being studied in a pivotal Phase 2b clinical trial in adults with primary mitochondrial myopathies (PMM).
